Mingxing Teng, Ph.D.

2022- Baylor College of Medicine, Houston, TX 
Chemical Biology, Medicinal Chemistry, Synthetic Chemistry
"Mingxing Teng"
Mean distance: (not calculated yet)
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Hassan MM, Li YD, Ma MW, et al. (2023) Exploration of the Tunability of BRD4 Degradation by DCAF16 -labelling Covalent Glues. Biorxiv : the Preprint Server For Biology
Teng M, Gray NS. (2023) The rise of degrader drugs. Cell Chemical Biology. 30: 864-878
Teng M, Jiang J, Wang ES, et al. (2023) Targeting the Dark Lipid Kinase PIP4K2C with a Potent and Selective Binder and Degrader. Angewandte Chemie (International Ed. in English). e202302364
Li YD, Ma MW, Hassan MM, et al. (2023) Template-assisted covalent modification of DCAF16 underlies activity of BRD4 molecular glue degraders. Biorxiv : the Preprint Server For Biology
Teng M, Young DW, Tan Z. (2022) The Pursuit of Enzyme Activation: A Snapshot of the Gold Rush. Journal of Medicinal Chemistry
Ye Q, Belabed H, Wang Y, et al. (2022) Advancing ASMS with LC-MS/MS for the discovery of novel PDCL2 ligands from DNA-Encoded chemical library selections. Andrology
Modukuri RK, Yu Z, Tan Z, et al. (2022) Discovery of potent BET bromodomain 1 stereoselective inhibitors using DNA-encoded chemical library selections. Proceedings of the National Academy of Sciences of the United States of America. 119: e2122506119
Teng M, Luskin MR, Cowan-Jacob SW, et al. (2022) The Dawn of Allosteric BCR-ABL1 Drugs: From a Phenotypic Screening Hit to an Approved Drug. Journal of Medicinal Chemistry
Teng M, Lu W, Donovan KA, et al. (2021) Development of PDE6D and CK1α Degraders through Chemical Derivatization of FPFT-2216. Journal of Medicinal Chemistry
Vervoort SJ, Devlin JR, Kwiatkowski N, et al. (2021) Targeting transcription cycles in cancer. Nature Reviews. Cancer. 22: 5-24
See more...